Sign up
Pharma Capital

Callitas Health bolsters cannabis products business by hiring industry expert as advisor

Dr Gregory Smith has become the firm's chief medical cannabis advisor, said Callitas
1526921753_shutterstock_547680163.jpg
Callitas reckons the appointment will help it to navigate the quickly evolving cannabis industry

Healthcare and pharma group Callitas Health Inc (CSE:LILY, OTCQB:MPHMF) has boosted its cannabis products business with the appointment of an industry expert, it told investors.

Dr Gregory Smith has become the firm's chief medical cannabis advisor.

READ - Callitas Health to focus on shareholder value in 2018, CEO Thompson says

"We believe the addition of Dr. Smith to the Callitas team will help us better navigate the quickly evolving cannabinoid industry and provide expert insight for our current products and future programs in research and development,” said James Thompson, interim president and chief executive.

"He brings a wealth of knowledge, clinical experience and insights that will be invaluable for our company’s growth."

Dr Smith, a former Major in the US army, has extensive experience and education in the field of cannabinoid medication.

He first trained on the use of medical cannabis in California in 2000, and subsequently, has published over a dozen peer-reviewed medical publications, two medical textbooks and “CBD (Cannabidiol) What You Need to Know”, Callitas revealed.

“I’ve been working with medical cannabis-related products for the last four years and am very excited to see what Callitas has in the pipeline,” said Dr Smith.

“The team at Callitas is focused on putting innovative technologies on the market, and I’m looking forward to helping Callitas bring these current and new projects to fruition, quickly and with best medical practices.”

READ - Callitas Health looks to line up partners for its cannabis-related products

Last month, Callitas said it was actively looking for business partners in states and countries where cannabis is legal.

It has signed partnership agreements with two undisclosed Californian companies, which permits Callitas to market and sell its CannaMint strips for both tetrahydrocannabinol (thc) and cannabidiol (cbd).

On the back of these tie-ups, Callitas hopes to reach similar agreements outside of California.

Giles_55af4ddca6481.jpg
Why Invest In Callitas Health Inc.? Read More Here

Register here to be notified of future LILY Company articles
View full LILY profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.